Gables Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Gables Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$54K	Hold	121	–	–	0.02%	217
2025 Q4	$54.9K	Hold	121	–	–	0.02%	212
2025 Q3	$47.4K	Hold	121	–	–	0.02%	217
2025 Q2	$53.9K	Hold	121	–	–	0.03%	201
2025 Q1	$58.7K	Hold	121	–	–	0.03%	201
2024 Q4	$48.7K	Hold	121	–	–	0.02%	212
2024 Q3	$56.3K	Hold	121	–	–	0.03%	204
2024 Q2	$56.7K	Hold	121	–	–	0.03%	193
2024 Q1	$50.6K	Hold	121	–	–	0.03%	198
2023 Q4	$49.2K	Hold	121	–	–	0.03%	194
2023 Q3	$42.1K	Hold	121	–	–	0.03%	192
2023 Q2	$42.6K	Hold	121	–	–	0.03%	205
2023 Q1	$38.1K	Hold	121	–	–	0.03%	212
2022 Q4	$34.9K	Hold	121	–	–	0.03%	218
2022 Q3	$35K	Hold	121	–	–	0.03%	213
2022 Q2	$34K	Hold	121	–	–	0.03%	227
2022 Q1	$32K	Hold	121	–	–	0.02%	237
2021 Q4	$27K	Hold	121	–	–	0.02%	245
2021 Q3	$22K	Hold	121	–	–	0.01%	255
2021 Q2	$24K	Hold	121	–	–	0.02%	250
2021 Q1	$26K	Hold	121	–	–	0.01%	271
2020 Q4	$29K	Hold	121	–	–	0.02%	248
2020 Q3	$33K	Hold	121	–	–	0.02%	228
2020 Q2	$35K	Hold	121	–	–	0.02%	219
2020 Q1	$29K	Buy	+121	New	+$27.8K	0.02%	228

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Gables Capital Management's VRTX Position: Q1 2026 in Review

Gables Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 121 shares worth $54K. The position accounts for 0.02% of the portfolio, ranked #217.

Gables Capital Management first reported a position in VRTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $58.7K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Gables Capital Management held 121 shares of Vertex Pharmaceuticals worth $54K as of Q1 2026.
Gables Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.02% of Gables Capital Management's portfolio in Q1 2026, its #217 holding.
Gables Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
Gables Capital Management's Vertex Pharmaceuticals position peaked at $58.7K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Gables Capital Management's 13F filing for Q1 2026, filed 1 May 2026.